Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 16752
Country/Region: Ethiopia
Year: 2015
Main Partner: Amhara Regional Health Bureau
Main Partner Program: NA
Organizational Type: Host Country Government Agency
Funding Agency: HHS/CDC
Total Funding: $9,434,100 Additional Pipeline Funding: $100,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,280,000
Care: TB/HIV (HVTB) $300,000
Care: Pediatric Care and Support (PDCS) $140,000
Laboratory Infrastructure (HLAB) $290,000
Strategic Information (HVSI) $271,300
Health Systems Strengthening (OHSS) $110,000
Biomedical Prevention: Blood Safety (HMBL) $78,800
Testing: HIV Testing and Counseling (HVCT) $180,000
Sexual Prevention: Other Sexual Prevention (HVOP) $164,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $850,000
Treatment: Adult Treatment (HTXS) $4,800,000
Treatment: Pediatric Treatment (PDTX) $970,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 135,373
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 17,130
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 2,828
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 16,147
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 78,825
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 92,575
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 501,009
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 269,136
HTS_TST By Test Result: Negative 2016 1,084,984
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 1,174,310
HTS_TST Sum of Aggregated Age/Sex <15 2016 171,400
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 770,145
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 941,545
HTS_TST Sum of Test Result disaggregates 2016 1,102,271
HTS_TST_POS By Test Result: Positive 2016 17,287
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 8
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 426
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 5,670
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 5,517
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 3,391
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 1,868
PMTCT_ARV Sum of New and Current disaggregates 2016 5,259
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 5,124
PMTCT_STAT By: Known positives at entry 2016 3,836
PMTCT_STAT By: Number of new positives identified 2016 1,665
PMTCT_STAT Number of new ANC and L&D clients 2016 353,706
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 331,919
PMTCT_STAT Sum of Positives Status disaggregates 2016 5,501
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 11,384
PP_PREV Total number of people in the target population 2016 13,862
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 132
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 138
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 135,373
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 18,268
TX_CURR Age/Sex: <1 Female 2016 347
TX_CURR Age/Sex: <1 Male 2016 455
TX_CURR Age/Sex: 1-4 Female 2016 1,351
TX_CURR Age/Sex: 1-4 Male 2016 1,528
TX_CURR Age/Sex: 5-14 Female 2016 2,694
TX_CURR Age/Sex: 5-14 Male 2016 2,596
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 127,747
TX_CURR Sum of age/sex disaggregates 2016 125,586
TX_NEW By Age/Sex: <1 Female 2016 76
TX_NEW By Age/Sex: <1 Male 2016 90
TX_NEW By Age/Sex: 1-4 Female 2016 247
TX_NEW By Age/Sex: 1-4 Male 2016 331
TX_NEW By Age/Sex: 10-14 Female 2016 182
TX_NEW By Age/Sex: 10-14 Male 2016 180
TX_NEW By Age/Sex: 15-19 Female 2016 206
TX_NEW By Age/Sex: 15-19 Male 2016 72
TX_NEW By Age/Sex: 20-24 Female 2016 1,586
TX_NEW By Age/Sex: 20-24 Male 2016 308
TX_NEW By Age/Sex: 25-49 Female 2016 7,820
TX_NEW By Age/Sex: 25-49 Male 2016 4,375
TX_NEW By Age/Sex: 5-9 Female 2016 349
TX_NEW By Age/Sex: 5-9 Male 2016 398
TX_NEW By Age/Sex: 50+ Female 2016 167
TX_NEW By Age/Sex: 50+ Male 2016 504
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 17,680
TX_NEW Sum of Age/Sex disaggregates 2016 16,891
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 15,424
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 18,247
Cross Cutting Budget Categories and Known Amounts Total: $2,490,520
Condoms: Policy, Tools, and Services $47,600
Key Populations: Sex Workers $95,340
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Training of health workers and community outreach workers
Water $47,600
Food and Nutrition: Policy, Tools, and Service Delivery $95,340
Gender: Gender Based Violence (GBV) $47,600
Post GBV Care
Implementation
Capacity building
Human Resources for Health $476,700
Education $95,340
Motor Vehicles: Purchased $585,000
Renovation $1,000,000